Top Insights
Rapport Therapeutics’ lead program could offer more targeted epilepsy treatment compared to currently available anti-seizure medications, which introduce many side effects. The IPO will support plans to develop the oral small molecule in focal epilepsy as well as chronic pain and bipolar disorder.
The post CNS-Focused Rapport Therapeutics Preps IPO to Back Phase 2-Ready Epilepsy Drug appeared first on MedCity News.
Recent Posts
Categories
Related Articles
How Should Healthcare Startups Approach Employers? 3 Execs Weigh In
During a panel at the MedCity News INVEST Digital Health conference, three...
As Medicaid Unwinding Concludes in Most States, KFF Finds 25 Million Lost Medicaid Coverage but Enrollment is 10 Million Higher Than Pre-Pandemic Levels
Over 25 million people were disenrolled from Medicaid and over 56 million...
Cultural Competence in Medical Tourism
Cultural sensitivity is a key factor when treating visitors from other nations...
Reporting Checklist for Discrete Choice Experiments in Health
What are the key elements for reporting your objective, attributes, experimental design,...
Leave a comment